Gsk (GSK) Research & Development (2009 - 2026)
Gsk (GSK) posted quarterly Research & Development of -$4.7 billion for Q2 2026, down 72.22% year-over-year from -$16.7 billion in Q2 2025, and down 103.86% quarter-over-quarter from -$2.3 billion in Q1 2026.
Gsk (GSK) Research & Development (2009 - 2026) Analysis & Trends
Gsk's Research & Development history runs 18 years deep, the most recent figure standing at -$4.7 billion for Q2 2026.
- In Q2 2026, Research & Development fell 72.22% year-over-year to -$4.7 billion; the TTM figure through Jun 2026 stood at -$19.2 billion (down 31.17% YoY), while the FY2025 annual figure was $9.9 billion, up 21.26% from the prior year.
- Research & Development for Q2 2026 stood at -$4.7 billion, down from -$2.3 billion in the prior quarter.
- The five-year high for Research & Development was -$1.5 billion in Q1 2022, with the low at -$10.0 billion in Q4 2025.
- The 5-year median for Research & Development is -$1.9 billion (2023), against an average of -$3.4 billion.
- Peak annual rise in Research & Development reached 18.74% in 2022, while the deepest fall reached 114.42% in 2022.
- Gsk's Research & Development stood at -$6.4 billion in 2022, then retreated by 19.99% to -$7.7 billion in 2023, then dropped by 6.37% to -$8.2 billion in 2024, then slipped by 21.83% to -$10.0 billion in 2025, then surged by 53.54% to -$4.7 billion in 2026.
- Business Quant data shows GSK's Research & Development at -$4.7 billion in Q2 2026, -$2.3 billion in Q1 2026, and -$10.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.65 Bn |
| Mar 31, 2026 | -2.28 Bn |
| Dec 31, 2025 | -10.01 Bn |
| Sep 30, 2025 | -2.28 Bn |
| Jun 30, 2025 | -2.70 Bn |
| Mar 31, 2025 | -1.84 Bn |
| Dec 31, 2024 | -8.22 Bn |
| Sep 30, 2024 | -1.90 Bn |
| Jun 30, 2024 | -1.86 Bn |
| Mar 31, 2024 | -1.82 Bn |
| Dec 31, 2023 | -7.72 Bn |
| Sep 30, 2023 | -2.00 Bn |
| Jun 30, 2023 | -1.68 Bn |
| Mar 31, 2023 | -1.53 Bn |
| Dec 31, 2022 | -6.44 Bn |
| Sep 30, 2022 | -1.59 Bn |
| Jun 30, 2022 | -1.56 Bn |
| Mar 31, 2022 | -1.48 Bn |
| Dec 31, 2021 | -3.00 Bn |
| Sep 30, 2021 | -1.95 Bn |